NZ527193A - Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives - Google Patents

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Info

Publication number
NZ527193A
NZ527193A NZ527193A NZ52719302A NZ527193A NZ 527193 A NZ527193 A NZ 527193A NZ 527193 A NZ527193 A NZ 527193A NZ 52719302 A NZ52719302 A NZ 52719302A NZ 527193 A NZ527193 A NZ 527193A
Authority
NZ
New Zealand
Prior art keywords
group
alkyl
heteroaryl
same
optionally substituted
Prior art date
Application number
NZ527193A
Other languages
English (en)
Inventor
Tao Wang
Zhongxing Zhang
Nicholas A Meanwell
John F Kadow
Zhiwei Yin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NZ527193A publication Critical patent/NZ527193A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ527193A 2001-02-02 2002-01-02 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives NZ527193A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26618301P 2001-02-02 2001-02-02
US31440601P 2001-08-23 2001-08-23
PCT/US2002/000455 WO2002062423A1 (en) 2001-02-02 2002-01-02 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Publications (1)

Publication Number Publication Date
NZ527193A true NZ527193A (en) 2004-05-28

Family

ID=26951680

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527193A NZ527193A (en) 2001-02-02 2002-01-02 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Country Status (31)

Country Link
US (1) US20030069266A1 (enExample)
EP (1) EP1363705B9 (enExample)
JP (1) JP4328527B2 (enExample)
KR (1) KR20030079979A (enExample)
CN (1) CN100384423C (enExample)
AR (1) AR034292A1 (enExample)
BG (1) BG66359B1 (enExample)
BR (1) BRPI0206636B8 (enExample)
CA (1) CA2437524C (enExample)
CY (1) CY1113194T1 (enExample)
CZ (1) CZ303750B6 (enExample)
DK (1) DK1363705T3 (enExample)
EE (1) EE05424B1 (enExample)
ES (1) ES2387981T3 (enExample)
HR (1) HRP20030694A2 (enExample)
HU (1) HU229305B1 (enExample)
IL (2) IL157029A0 (enExample)
IS (1) IS2912B (enExample)
MX (1) MXPA03006939A (enExample)
MY (1) MY137480A (enExample)
NO (1) NO326510B1 (enExample)
NZ (1) NZ527193A (enExample)
PE (1) PE20020855A1 (enExample)
PL (1) PL364279A1 (enExample)
PT (1) PT1363705E (enExample)
RS (1) RS52489B (enExample)
RU (1) RU2303038C2 (enExample)
SK (1) SK287900B6 (enExample)
TW (1) TWI318978B (enExample)
WO (1) WO2002062423A1 (enExample)
ZA (1) ZA200305885B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040162298A1 (en) * 2002-02-23 2004-08-19 Hsu-Tso Ho Method of treating HIV infection by preventing interaction of CD4 and gp120
US7348337B2 (en) 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
NZ540148A (en) 2002-12-20 2007-11-30 Glaxo Group Ltd Benzazepine derivatives for the treatment of neurological disorders
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US20050124623A1 (en) * 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
CN1953985B (zh) * 2004-03-15 2010-06-09 布里斯托尔-迈尔斯斯奎布公司 哌嗪和取代的哌啶抗病毒药物的前药
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
JP4989478B2 (ja) 2004-09-03 2012-08-01 ユーハン・コーポレイション ピロロ[3,2−b]ピリジン誘導体及びその製造方法
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US8318941B2 (en) * 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8236835B2 (en) * 2006-09-22 2012-08-07 Novartis Ag Heterocyclic inhibitors of stearoyl-CoA desaturase
EP2313408B1 (en) 2008-06-25 2012-07-11 Bristol-Myers Squibb Company Diketopiperidine derivatives as hiv attachment inhibitors
EP2303876B1 (en) 2008-06-25 2014-03-19 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
BR112014019289A8 (pt) 2012-02-08 2017-07-11 Bristol Myers Squibb Co Métodos para a preparação do composto de prome-dicamento de piperazina inibidor da ligação do hiv
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
BR112015009751A2 (pt) 2012-10-31 2017-07-11 Bayer Cropscience Ag novos compostos heterocíclicos como pesticidas
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US12129255B2 (en) 2019-06-19 2024-10-29 Viiv Healthcare Uk (No. 5) Limited Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
US11862306B1 (en) 2020-02-07 2024-01-02 Cvs Pharmacy, Inc. Customer health activity based system for secure communication and presentation of health information

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
GB9420521D0 (en) * 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
MXPA01011976A (es) * 1999-05-21 2002-05-06 Scios Inc Derivados de tipo indol como inhibidores de cinasa p38.
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
EP1208097B1 (en) * 1999-07-28 2009-02-18 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
MXPA02006338A (es) * 1999-12-24 2002-12-13 Aventis Pharma Ltd Azaindoles.
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
EP1299382B1 (en) * 2000-07-10 2005-09-21 Bristol-Myers Squibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives

Also Published As

Publication number Publication date
IL157029A (en) 2015-11-30
WO2002062423A1 (en) 2002-08-15
CA2437524A1 (en) 2002-08-15
PE20020855A1 (es) 2002-09-27
SK287900B6 (sk) 2012-03-02
IL157029A0 (en) 2004-02-08
DK1363705T3 (da) 2012-09-24
AR034292A1 (es) 2004-02-18
BRPI0206636B1 (pt) 2018-05-02
YU60903A (sh) 2006-05-25
CY1113194T1 (el) 2016-04-13
KR20030079979A (ko) 2003-10-10
BR0206636A (pt) 2004-02-25
IS2912B (is) 2014-11-15
NO20033436D0 (no) 2003-08-01
CA2437524C (en) 2010-04-27
EP1363705A1 (en) 2003-11-26
MY137480A (en) 2009-01-30
NO20033436L (no) 2003-10-01
ZA200305885B (en) 2005-01-26
EP1363705B1 (en) 2012-06-13
HUP0304062A3 (en) 2010-06-28
BRPI0206636B8 (pt) 2021-05-25
RS52489B (sr) 2013-02-28
CN100384423C (zh) 2008-04-30
BG108021A (bg) 2004-04-30
RU2003127077A (ru) 2005-03-20
BG66359B1 (bg) 2013-09-30
HRP20030694A2 (en) 2005-04-30
CZ303750B6 (cs) 2013-04-17
PL364279A1 (en) 2004-12-13
PT1363705E (pt) 2012-08-17
CN1612763A (zh) 2005-05-04
IS6899A (is) 2003-07-30
CZ20032316A3 (cs) 2004-01-14
SK9592003A3 (en) 2004-08-03
EP1363705B9 (en) 2012-11-07
NO326510B1 (no) 2008-12-22
HU229305B1 (en) 2013-10-28
JP2004522755A (ja) 2004-07-29
EE05424B1 (et) 2011-06-15
ES2387981T3 (es) 2012-10-05
RU2303038C2 (ru) 2007-07-20
EP1363705A4 (en) 2009-08-12
EE200300359A (et) 2003-12-15
HUP0304062A2 (hu) 2004-04-28
HK1056698A1 (en) 2004-02-27
TWI318978B (en) 2010-01-01
JP4328527B2 (ja) 2009-09-09
MXPA03006939A (es) 2003-11-18
US20030069266A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
CA2437524C (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7662823B2 (en) Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives
AU2009202361B2 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
AU2002241824B2 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
AU2002241824A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HK1056698B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JAN 2016 BY CPA GLOBAL

Effective date: 20141204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JAN 2017 BY CPA GLOBAL

Effective date: 20151204

ASS Change of ownership

Owner name: VIIV HEALTHCARE UK (NO.4) LIMITED, GB

Effective date: 20161124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JAN 2018 BY THOMSON REUTERS

Effective date: 20161214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JAN 2019 BY THOMSON REUTERS

Effective date: 20171214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JAN 2020 BY THOMSON REUTERS

Effective date: 20181220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JAN 2021 BY THOMSON REUTERS

Effective date: 20191217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JAN 2022 BY THOMSON REUTERS

Effective date: 20201215

EXPY Patent expired